Psyence Biomedical Shares Are Trading Higher After the Company Announced the Recruitment of Its Australia-based Empax Center as the Second Trial Site for Psyence's Biomed Ongoing Phase IIb Clinical Trial of Nature-derived Psilocybin as a Potential...

Psyence生物醫藥股價上漲，因該公司宣佈其位於澳洲的Empax中心成爲Psyence生物正在進行的第二階段IIb自然來源的哌噠質酸臨床試驗的招募地點。

Benzinga · 2024/10/25 21:48

Psyence Biomedical Shares Are Trading Higher After the Company Announced the Recruitment of Its Australia-based Empax Center as the Second Trial Site for Psyence's Biomed Ongoing Phase IIb Clinical Trial of Nature-derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care.

Psyence 生物醫藥股份上漲，因公司宣佈招募其位於澳洲的 Empax 中心作爲 Psyence 生物進行的自然來源的快速秋水仙素生物進行中的第二個臨床試驗地點，以作爲潛在的治療臨終關懷中的調適障礙的第二階段 IIb 臨床試驗。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。